Fujifilm starts new late-phase trial of Avigan in Japan for COVID-19 patients
- Wall Street ends with broad sell-off on spiking inflation fears
- Fed Has Already Changed its Policy Due to Inflation, Market Gambling Fears - Dick Bove
- U.S. consumer prices post largest gain since 2009 as inflation ramps up
- Bill Ackman said has he been working on a transaction for Pershing Square Tontine (PSTH) for months
- Silvergate Capital (SI) to be the Exclusive Issuer of U.S. Dollar Backed Stablecoins by Diem (FB)
FILE PHOTO: Tablets of Avigan are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo. REUTERS/Issei Kato
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
TOKYO (Reuters) -Fujifilm Holdings Corp said on Wednesday it started a new phase III trial in Japan of its Avigan drug for COVID-19, reviving hopes for a home-grown treatment for the virus.
Domestic approval for the antiviral drug to treat the coronavirus was dealt a setback in December after a health ministry panel said that trial data was inconclusive.
Fujifilm has over the years pivoted from its traditional camera and office solutions businesses to health care. [nT9N2LY00R
The new double-blind, placebo-controlled study is targeting patients aged 50 and older, as well as those at risk of developing serious conditions, Fujifilm said in a release.
Avigan, known generically as favipiravir, has been studied in dozens of trials worldwide, and it has been approved as a COVID-19 treatment in Russia, India and Indonesia. But concerns remain, as the drug has been shown to cause birth defects in animal studies.
Japan has already approved Avigan as an emergency flu medicine, and the government last year called on Fujifilm to triple national stockpiles of the drug.
(Reporting by Rocky Swift; Editing by Jacqueline Wong and Ana Nicolaci da Costa)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. safety agency opens probe of Tesla fatal crash in California
- mRNA vaccines appear effective vs India variant; people with HIV at higher risk for severe COVID-19
- Facebook-backed crypto project Diem to launch U.S. stablecoin in major shift
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!